* Capricor Therapeutics Inc reported a quarterly adjusted loss of 38 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of six analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -49 cents to -31 cents per share.
* Revenue fell 63.4% to $2.26 million from a year ago; analysts expected $3.57 million.
* Capricor Therapeutics Inc's reported EPS for the quarter was a loss of 38 cents.
* The company reported a quarterly loss of $12.56 million.
* Capricor Therapeutics Inc shares had risen by 19.0% this quarter and gained 270.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 2.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Capricor Therapeutics Inc is $32.50 This summary was machine generated from LSEG data November 14 at 04:03 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.36 -0.38 Missed
Jun. 30 2024 -0.36 -0.35 Beat
Mar. 31 2024 -0.11 -0.31 Missed
Dec. 31 2023 -0.09 -0.02 Beat